Longboard Pharmaceuticals Inc

Company Profile

longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.